Vijayasree Arvind, MD
Pain Medicine · Dallas, TXNPI 1104861020
Payments from drug & device makers
Across 254 payments — averaging $36.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Si-bone, Inc.$2K
- Nevro Corp.$905
- Boston Scientific$746
- Amgen$632
- Teva Pharmaceuticals USA, Inc.$482
- plus $3K from 30 others
What the payments were for
- Travel & lodging$1,31714%
- Food & beverage$7,80985%
- Education$420%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 22 | $1,659 |
| Si-bone, Inc. | 19 | $1,640 |
| Nevro Corp. | 11 | $905 |
| Boston Scientific | 9 | $746 |
| Amgen | 17 | $632 |
| Teva Pharmaceuticals USA, Inc. | 34 | $482 |
| Scilex Pharmaceuticals Inc. | 19 | $365 |
| Collegium Pharmaceutical, Inc. | 19 | $327 |
| AbbVie(2 entities) | 11 | $259 |
| Daiichi Sankyo Inc. | 13 | $256 |
| Vertos Medical, Inc. | 4 | $225 |
| SPR Therapeutics, Inc | 3 | $180 |
| Abbott | 8 | $170 |
| Lundbeck LLC | 7 | $155 |
| Pfizer | 8 | $154 |
| Lilly USA, LLC | 7 | $125 |
| Saluda Medical Americas, Inc. | 5 | $123 |
| Averitas Pharma Inc. | 2 | $110 |
| Biodelivery Sciences International, Inc. | 7 | $106 |
| Johnson & Johnson | 2 | $64 |
| Hikma Pharmaceuticals USA | 3 | $63 |
| Novartis | 4 | $61 |
| Valinor Pharma, LLC | 2 | $44 |
| Arbor Pharmaceuticals, Inc. | 2 | $42 |
| Avanos Medical | 2 | $38 |
| Vertex | 2 | $34 |
| IBSA Pharma Inc. | 2 | $29 |
| GRT US Holding, Inc. | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Redhill Biopharma Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Shionogi Inc | 1 | $19 |
| Forte Bio-pharma LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
| Electronic Waveform Lab, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IFUSE IMPLANT SYSTEM$922
- VANTA ADAPTIVESTIM$583
- Senza Spinal Cord Stimulation System$413
- WaveWriter Alpha Prime 16$384
- AIMOVIG$342
- iFuse Implant$257
- Omnia$243
- INTELLIS ADAPTIVESTIM$183
- INTELLIS$146
- ADAPTIVESTIM$129
- Morphabond ER$125
- QULIPTA$124
- UBRELVY$124
- SPRINT PNS System$114
- RESTORE$114
How this compares
$9,168 in reported general payments places this provider in the 75th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 239 | $50,905 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,064 | $28,618 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 1,334 | $21,633 |
| UbrelvyUbrogepant | 11 | $17,689 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,789 |
| Diclofenac Epolamine | 13 | $8,337 |
| BelbucaBuprenorphine Hcl | 19 | $8,075 |
| Gabapentin | 547 | $7,977 |
| Tramadol Hcl ErTramadol Hcl | 130 | $7,112 |
| Lidocaine | 50 | $6,664 |
| Tramadol Hcl | 674 | $6,446 |
| Pregabalin | 342 | $5,136 |
| Diclofenac Sodium | 88 | $4,348 |
| Cyclobenzaprine Hcl | 382 | $2,691 |
| Methocarbamol | 233 | $2,564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $63 | $51,194253 claims |
| AbbVieUbrelvy | $259 | $17,68911 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $327 | $8,07519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 583 pain medicine providers in Texas.
Other pain medicine in Dallas
- Muhammad ZulqarnainDallas$556K
- Amol PatwardhanDallas$177K
- Justin ThompsonDallas$45K
- Demaceo HowardDallas$39K
- Aaron CalodneyTyler$3M
- Mitchell EngleHouston$1.5M
- Melissa MurphyGrapevine$711K
- Shiraz YazdaniLubbock$632K
- Daniel PakHouston$460K
- Marvin ChangSugar Land$306K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.